Table 1.
Summary literature search.
| Mother | Herold 2001 | Kimby 2004 | Friedrichs 2006 | Scully M 2006 | Ojeda-Uribe 2006 | Magloire 2006 | Decker 2006 | Current study |
|---|---|---|---|---|---|---|---|---|
| Condition | B-cell lymphoma | NH-lymphoma | Burkitt lymphoma | Thrombotic Thrombocytopenic Purpura | Autoimmune Haemolytic anaemia | Burkitt lymphoma | B-cell-NH lymphoma | ITP |
| Rituximab 375 mg/m2 | Weekly 4x | Weekly 4x | Weekly 4x | Weekly 4x | — | — | Biweekly 6x | Weekly 4X |
| Co medication | CHOP(1) | — | CHOP | Plasma exchange | Corticosteroids | CHOP | CHOP | Prednisone, IgG |
| Administration time GA | Week 21 | Week -1 to 3 | Weeks 16–30 | Week 27 | Week 10 | Week 13 to ? | Weeks 16-28 | Week 30 to 34 |
| Rituximab level D0(2)(ng/mL) | — | — | 9750 | — | — | — | 25000 | 24000 |
| CD19+ B-cells D0 (1 × 109/L) | — | — | 0 | — | — | — | 0 | 0 |
| Child | — | — | — | — | — | — | — | — |
| GA (weeks) | 35 | 40 | 41 | 30 | 38 | 39 | 33 | 38 |
| Rituximab level D0 (ng/mL) | — | — | 32095 | — | — | — | 30000 | 6700 |
| CD19+ B-cells (1 × 109/L) < week 1 post partum | — | 0,1 | 0 | — | 0,66 | — | approx 0,05 | 0,08 |
| CD19+ B-cells (1 × 109/L) 1 month | normal | — | — | — | 1,98 | — | — | 0,00 |
| CD19+ B-cells (1 × 109/L) 3 months | — | — | — | — | — | — | — | 0,21 |
| CD19+ B-cells (1 × 109/L) 6 months | — | — | — | — | — | — | — | 2 |
| Vaccination titres | — | Normal | Normal | — | — | — | Normal | normal |
| IgA; IgM; IgG (g/L) 1-2 months | — | — | — | — | 0,07; 0,3; 4,5- | — | — | <0,07; 0,05; 6,1 |
| IgA; IgM; IgG (g/L) 3 months | — | — | — | — | — | — | — | <0,07; <0,04; 2,8 |
| IgA; IgM; IgG (g/L) ≥6 months | — | IgG normal | Normal | — | — | — | Normal | 0,16; 0,53; 2,2 |
(1) Cyclophosphamid, doxorubicin, vincristin, prednisolon.
(2) Day of birth.